ALNYLAM PHARMACEUTICALS INC (DUL.DE) Fundamental Analysis & Valuation

FRA:DUL • US02043Q1076

Current stock price

263.1 EUR
-11.5 (-4.19%)
Last:

This DUL.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. DUL.DE Profitability Analysis

1.1 Basic Checks

  • DUL had positive earnings in the past year.
  • In the past year DUL had a positive cash flow from operations.
  • DUL had negative earnings in 4 of the past 5 years.
  • In multiple years DUL reported negative operating cash flow during the last 5 years.
DUL.DE Yearly Net Income VS EBIT VS OCF VS FCFDUL.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M -1B

1.2 Ratios

  • The Return On Assets of DUL (6.32%) is better than 79.75% of its industry peers.
  • DUL's Return On Equity of 39.76% is amongst the best of the industry. DUL outperforms 96.20% of its industry peers.
  • DUL has a Return On Invested Capital of 10.09%. This is amongst the best in the industry. DUL outperforms 86.08% of its industry peers.
Industry RankSector Rank
ROA 6.32%
ROE 39.76%
ROIC 10.09%
ROA(3y)-3.91%
ROA(5y)-13.41%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DUL.DE Yearly ROA, ROE, ROICDUL.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400 -400 600

1.3 Margins

  • With a decent Profit Margin value of 8.45%, DUL is doing good in the industry, outperforming 75.95% of the companies in the same industry.
  • With a decent Operating Margin value of 13.51%, DUL is doing good in the industry, outperforming 79.75% of the companies in the same industry.
  • DUL has a Gross Margin of 81.64%. This is in the better half of the industry: DUL outperforms 69.62% of its industry peers.
  • In the last couple of years the Gross Margin of DUL has remained more or less at the same level.
Industry RankSector Rank
OM 13.51%
PM (TTM) 8.45%
GM 81.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.84%
GM growth 5Y-0.6%
DUL.DE Yearly Profit, Operating, Gross MarginsDUL.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. DUL.DE Health Analysis

2.1 Basic Checks

  • DUL has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • DUL has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for DUL has been increased compared to 5 years ago.
  • Compared to 1 year ago, DUL has an improved debt to assets ratio.
DUL.DE Yearly Shares OutstandingDUL.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
DUL.DE Yearly Total Debt VS Total AssetsDUL.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • DUL has an Altman-Z score of 5.63. This indicates that DUL is financially healthy and has little risk of bankruptcy at the moment.
  • DUL has a better Altman-Z score (5.63) than 74.68% of its industry peers.
  • The Debt to FCF ratio of DUL is 5.80, which is a neutral value as it means it would take DUL, 5.80 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 5.80, DUL belongs to the top of the industry, outperforming 82.28% of the companies in the same industry.
  • A Debt/Equity ratio of 3.14 is on the high side and indicates that DUL has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 3.14, DUL is doing worse than 60.76% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 3.14
Debt/FCF 5.8
Altman-Z 5.63
ROIC/WACC1.08
WACC9.33%
DUL.DE Yearly LT Debt VS Equity VS FCFDUL.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B

2.3 Liquidity

  • A Current Ratio of 2.76 indicates that DUL has no problem at all paying its short term obligations.
  • DUL has a Current ratio (2.76) which is comparable to the rest of the industry.
  • A Quick Ratio of 2.71 indicates that DUL has no problem at all paying its short term obligations.
  • DUL has a Quick ratio of 2.71. This is in the better half of the industry: DUL outperforms 63.29% of its industry peers.
Industry RankSector Rank
Current Ratio 2.76
Quick Ratio 2.71
DUL.DE Yearly Current Assets VS Current LiabilitesDUL.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. DUL.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 191.24% over the past year.
  • The Revenue has grown by 65.19% in the past year. This is a very strong growth!
  • Measured over the past years, DUL shows a very strong growth in Revenue. The Revenue has been growing by 49.77% on average per year.
EPS 1Y (TTM)191.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%226.15%
Revenue 1Y (TTM)65.19%
Revenue growth 3Y52.98%
Revenue growth 5Y49.77%
Sales Q2Q%84.95%

3.2 Future

  • The Earnings Per Share is expected to grow by 64.83% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, DUL will show a very strong growth in Revenue. The Revenue will grow by 24.60% on average per year.
EPS Next Y276.83%
EPS Next 2Y137.42%
EPS Next 3Y94.79%
EPS Next 5Y64.83%
Revenue Next Year48.81%
Revenue Next 2Y40.31%
Revenue Next 3Y32.91%
Revenue Next 5Y24.6%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
DUL.DE Yearly Revenue VS EstimatesDUL.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
DUL.DE Yearly EPS VS EstimatesDUL.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

5

4. DUL.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • DUL is valuated quite expensively with a Price/Earnings ratio of 153.86.
  • 72.15% of the companies in the same industry are more expensive than DUL, based on the Price/Earnings ratio.
  • DUL's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 25.54.
  • A Price/Forward Earnings ratio of 40.89 indicates a quite expensive valuation of DUL.
  • DUL's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. DUL is cheaper than 73.42% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.70, DUL is valued quite expensively.
Industry RankSector Rank
PE 153.86
Fwd PE 40.89
DUL.DE Price Earnings VS Forward Price EarningsDUL.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, DUL is valued a bit cheaper than 75.95% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of DUL indicates a rather cheap valuation: DUL is cheaper than 81.01% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 86.94
EV/EBITDA 69.99
DUL.DE Per share dataDUL.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as DUL's earnings are expected to grow with 94.79% in the coming years.
PEG (NY)0.56
PEG (5Y)N/A
EPS Next 2Y137.42%
EPS Next 3Y94.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DUL.DE Dividend Analysis

5.1 Amount

  • No dividends for DUL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DUL.DE Fundamentals: All Metrics, Ratios and Statistics

ALNYLAM PHARMACEUTICALS INC

FRA:DUL (3/23/2026, 7:00:00 PM)

263.1

-11.5 (-4.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)04-29
Inst Owners101.56%
Inst Owner ChangeN/A
Ins Owners0.22%
Ins Owner ChangeN/A
Market Cap34.89B
Revenue(TTM)3.71B
Net Income(TTM)313.75M
Analysts80
Price Target408.75 (55.36%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)74.34%
Min EPS beat(2)-28.48%
Max EPS beat(2)177.15%
EPS beat(4)3
Avg EPS beat(4)59.12%
Min EPS beat(4)-28.48%
Max EPS beat(4)177.15%
EPS beat(8)6
Avg EPS beat(8)47.92%
EPS beat(12)9
Avg EPS beat(12)45.85%
EPS beat(16)10
Avg EPS beat(16)29.15%
Revenue beat(2)1
Avg Revenue beat(2)8.48%
Min Revenue beat(2)-8.27%
Max Revenue beat(2)25.23%
Revenue beat(4)2
Avg Revenue beat(4)7.97%
Min Revenue beat(4)-8.27%
Max Revenue beat(4)25.23%
Revenue beat(8)4
Avg Revenue beat(8)10.34%
Revenue beat(12)6
Avg Revenue beat(12)13.44%
Revenue beat(16)7
Avg Revenue beat(16)7.94%
PT rev (1m)-7.48%
PT rev (3m)3.87%
EPS NQ rev (1m)-30.56%
EPS NQ rev (3m)-23.81%
EPS NY rev (1m)11.38%
EPS NY rev (3m)7.22%
Revenue NQ rev (1m)-7.37%
Revenue NQ rev (3m)-6.23%
Revenue NY rev (1m)3.11%
Revenue NY rev (3m)4.22%
Valuation
Industry RankSector Rank
PE 153.86
Fwd PE 40.89
P/S 10.89
P/FCF 86.94
P/OCF 77.2
P/B 51.27
P/tB 51.27
EV/EBITDA 69.99
EPS(TTM)1.71
EY0.65%
EPS(NY)6.43
Fwd EY2.45%
FCF(TTM)3.03
FCFY1.15%
OCF(TTM)3.41
OCFY1.3%
SpS24.15
BVpS5.13
TBVpS5.13
PEG (NY)0.56
PEG (5Y)N/A
Graham Number14.05
Profitability
Industry RankSector Rank
ROA 6.32%
ROE 39.76%
ROCE 14.33%
ROIC 10.09%
ROICexc 59.7%
ROICexgc 59.7%
OM 13.51%
PM (TTM) 8.45%
GM 81.64%
FCFM 12.53%
ROA(3y)-3.91%
ROA(5y)-13.41%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.84%
GM growth 5Y-0.6%
F-Score6
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 3.14
Debt/FCF 5.8
Debt/EBITDA 4.45
Cap/Depr 105.46%
Cap/Sales 1.58%
Interest Coverage 2.29
Cash Conversion 94.05%
Profit Quality 148.33%
Current Ratio 2.76
Quick Ratio 2.71
Altman-Z 5.63
F-Score6
WACC9.33%
ROIC/WACC1.08
Cap/Depr(3y)93.68%
Cap/Depr(5y)120.71%
Cap/Sales(3y)2.17%
Cap/Sales(5y)4.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)191.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%226.15%
EPS Next Y276.83%
EPS Next 2Y137.42%
EPS Next 3Y94.79%
EPS Next 5Y64.83%
Revenue 1Y (TTM)65.19%
Revenue growth 3Y52.98%
Revenue growth 5Y49.77%
Sales Q2Q%84.95%
Revenue Next Year48.81%
Revenue Next 2Y40.31%
Revenue Next 3Y32.91%
Revenue Next 5Y24.6%
EBIT growth 1Y383.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year126.01%
EBIT Next 3Y65%
EBIT Next 5Y46.92%
FCF growth 1Y1192.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6405.1%
OCF growth 3YN/A
OCF growth 5YN/A

ALNYLAM PHARMACEUTICALS INC / DUL.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ALNYLAM PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 6 / 10 to DUL.DE.


What is the valuation status of ALNYLAM PHARMACEUTICALS INC (DUL.DE) stock?

ChartMill assigns a valuation rating of 5 / 10 to ALNYLAM PHARMACEUTICALS INC (DUL.DE). This can be considered as Fairly Valued.


What is the profitability of DUL stock?

ALNYLAM PHARMACEUTICALS INC (DUL.DE) has a profitability rating of 5 / 10.


Can you provide the financial health for DUL stock?

The financial health rating of ALNYLAM PHARMACEUTICALS INC (DUL.DE) is 6 / 10.